Mar 8, 2017
Otsuka Pharmaceutical Acquiring Neurovance
Otsuka Pharmaceutical Acquiring Neurovance
Mar 3, 2017
In an effort to expand the portfolio of central nervous system-based therapies, Otsuka Pharmaceutical will acquire Neurovance Inc. in a transaction that could be worth as much as $250 million.
As per the deal, Otsuka subsidiary Otsuka America Inc. will pay $100 million at closing and as much as $150 million based on approval and sale milestones tied to the continuing development of…
View On WordPress